This review summarizes the biological and clinical features of various biomarkers for the diagnosis, prognosis, and treatment follow-up of community-acquired pneumonia.
Biomarker profiles in CAP remain investigational; leaves open prospective validation before any clinical integration.
Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Biomarkers are useful tools for searching for antibiotic therapy modifications and for CAP diagnosis, prognosis and follow-up treatment. This non-systematic state-of-the-art review presents the biological and clinical features of biomarkers in CAP patients, including procalcitonin, C-reactive protein, copeptin, pro-ANP (atrial natriuretic peptide), adrenomedullin, cortisol and D-dimers.
No takes yet. Share an insight, caveat, or question.
Seligman et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: